BioPharmSignal logoBioPharmSignal

Biotech News

Jaguar Health Reports First Quarter 2026 Financials

Jaguar Health (JAGX)Jaguar HealthEarnings

Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025, buoyed by license of U.S. commercial rights for Mytesi ® and Canalevia ® -CA1 Company continues its focus on crofelemer development efforts for rare-disease intestinal failure indications; two crofelemer

Open original release

Related news

SCYXSCYNEXIS2026-05-11 20:23 EST

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

IBRXImmunityBio2026-04-09 11:30 EST

ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities

JAGXJaguar Health2026-05-20 13:00 EST

Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference

JAGXJaguar Health2026-04-07 12:30 EST

Jaguar Health Reports 2025 Financials

SCYXSCYNEXIS2025-11-05 21:20 EST

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

VIRXViracta Therapeutics2024-11-13 12:00 EST

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

ALZNAlzamend Neuro2025-07-23 12:00 EST

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

IBRXImmunityBio2026-04-21 11:30 EST

ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership

View all latest news

Jaguar Health

Jaguar Health is a biopharmaceutical company focused on gastrointestinal and rare-disease therapies, with Mytesi as a key commercial asset. Its story combines niche commercialization with a pipeline aimed at high-unmet-need GI indications.

Recent company news

JAGXJaguar Health2026-05-28 14:00 EST

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders

JAGXJaguar Health2026-05-27 13:00 EST

Jaguar Health Compliant with Nasdaq Bid Price Rule

JAGXJaguar Health2026-05-20 20:40 EST

Jaguar Health Reports First Quarter 2026 Financials

JAGXJaguar Health2026-05-20 13:00 EST

Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference

JAGXJaguar Health2026-05-19 13:00 EST

Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer

Stock data

Close
1.00 USD
Market cap
2.12M USD
Exchange
NASDAQ
Sector
Biopharma
Location
San Francisco, California